关于
  • English
  • About
    • About Sirona
    • Management
    • Board of Directors
    • Strategic Advisory Board
    • Our Partners
  • TFChem
    • About TFChem
    • Management
    • Team
    • TFChem Laboratory Capabilities
  • Programs
    • Proprietary Platform Technology
    • Pipeline
    • Diabetes – SGLT2 Inhibitor
    • Skincare – Dark Spot Correction
    • Skincare – Anti-Aging / Anti-Wrinkle
    • Antiviral
  • News
    • Sirona News
    • Events
  • Investors
    • Financial Information
    • Financial Reports
    • Investor & Media Kit
    • Newsletter
  • Contact
  • Careers

News

Sirona Biochem Welcomes Claude Nivet, New Laboratory Operations Manager at TFChem

March 26th, 2014

Vancouver, British Columbia – March 26, 2014 – Sirona Biochem Corp. (TSX-V: SBM.V OTCQX: SRBCF, Frankfurt: ZSB) Sirona Biochem is pleased to announce that Claude Nivet has joined TFChem in the newly created position of Laboratory Operations Manager. Claude’s responsibilities include leading the plan to expand TFChem’s physical structure and scientific team.

Claude brings more than 30 years of experience working in pharmaceutical companies and will report directly to Dr. Geraldine Deliencourt-Godefroy. Claude will manage the daily operations of TFChem, enabling Dr. Deliencourt-Godefroy to focus on leading the scientific advancement of our proprietary technology and R&D pipeline.

“We are excited to have Claude join our team at TFChem,” states Neil Belenkie, CEO of Sirona Biochem. “Claude has a proven track record leading laboratories through their growth strategies and he will create and manage the organizational structure required to support long term, efficient operations at TFChem”.

About Sirona Biochem

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds’ efficacy and safety. Sirona Biochem’s compounds are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem’s wholly-owned French laboratory is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information regarding this press release, contact:

Christopher Hopton
CFO
Sirona Biochem Corp.
Phone:  1.604.282.6064
Email: chopton@sironabiochem.com

———————————————

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.

Archives

  • About
  • TFChem
  • Programs
  • News
  • Investors
  • Contact

© 2023 Sirona Biochem.

Sirona Biochem Corp
c/o WeWork
595 Burrard St.
Vancouver, B.C., Canada,V7X 1L4

TFCHEM
Voie de l’innovation
Pharma Parc II Chaussée du Vexin
27100 Val de Reuil, France

General inquires: 604.641.4466
Investor inquiries (Momentum PR): 450.332.6939
info@sironabiochem.com

© 2023 Sirona Biochem.

Sirona Biochem Corp
c/o WeWork
595 Burrard St.
Vancouver, B.C., Canada,V7X 1L4

TFCHEM
Voie de l’innovation
Pharma Parc II Chaussée du Vexin
27100 Val de Reuil, France

General inquires: 604.641.4466
Investor inquiries (Momentum PR): 450.332.6939
info@sironabiochem.com

Enter your info below to subscribe to our newsletter:
Loading